Compare Merck & Co., Inc. (MRK) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Value Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $133.32 (market cap $321.77B), while Vanguard Value Index Fund ETF trades at $226.36. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals.
| MRK | VTV | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | — |
52-Week High | $131.84 | $225.35 |
52-Week Low | $77.60 | $179.43 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Vanguard Value ETF (VTV) trades at $226.09, up 0.48% with bullish technical signals from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026, with one Vanguard deep-value fund reportedly up 22% year-to-date according to 247 Wallst on August 10, 2026. Recent institutional activity shows mixed positioning with some firms reducing stakes while others increased holdings.
The outlook remains positive as value strategies gain traction amid tech sector volatility. Key risks include concentration in value stocks and market rotation patterns. Institutional interest persists despite some profit-taking, suggesting continued confidence in the value premium.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
